Bristol-Myers CEO Caforio Announces Retirement
Christopher Boerner, chief commercialization officer, set to succeed Caforio in November.
Bristol-Myers Squibb CEO Giovanni Caforio is set to retire, with Chief Commercialization Officer Christopher Boerner taking over the position on November 1. Caforio, who has been at the helm since 2015, will continue in his role as executive chairman. Under his leadership, the company cemented its status as a leading cancer treatment provider, most notably through the $74 billion acquisition of Celgene in 2019.
Caforio's successor, Christopher Boerner, joined Bristol-Myers in 2015 and has held the role of Chief Commercialization Officer since 2018. He has overseen the company's commercial and medical units and managed key franchises. Read our profile on Christopher Boerner.
The change in leadership comes as Bristol-Myers prepares to lose patent protection on major products like Opdivo and blood thinner Eliquis. The company anticipates new drugs to generate at least $25 billion in sales by 2030.
Reference: Bristol-Myers CEO Giovanni Caforio to Step Down. April 26, 2023 / Wall Street Journal
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
